INFI Annual EBIT
-$44.19 M
+$893.00 K+1.98%
31 December 2022
Summary:
As of January 21, 2025, INFI annual earnings before interest & taxes is -$44.19 million, with the most recent change of +$893.00 thousand (+1.98%) on December 31, 2022. During the last 3 years, it has risen by +$359.00 thousand (+0.81%).INFI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI Quarterly EBIT
-$9.91 M
+$1.09 M+9.90%
30 June 2023
Summary:
As of January 21, 2025, INFI quarterly earnings before interest & taxes is -$9.91 million, with the most recent change of +$1.09 million (+9.90%) on June 30, 2023. Over the past year, it has increased by +$2.03 million (+17.00%).INFI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI TTM EBIT
-$40.77 M
+$2.03 M+4.74%
30 June 2023
Summary:
As of January 21, 2025, INFI TTM earnings before interest & taxes is -$40.77 million, with the most recent change of +$2.03 million (+4.74%) on June 30, 2023. Over the past year, it has increased by +$5.84 million (+12.53%).INFI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INFI EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2.0% | +17.0% | +12.5% |
| 3 y3 years | +0.8% | -11.8% | +0.1% |
| 5 y5 years | -6.4% | -42.3% | +8.5% |
INFI EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | -272.3% | -109.2% | -272.2% |
Infinity Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$9.91 M(-9.9%) | -$40.77 M(-4.7%) |
| Mar 2023 | - | -$11.00 M(+19.8%) | -$42.80 M(-3.1%) |
| Dec 2022 | -$44.19 M(-2.0%) | -$9.19 M(-13.9%) | -$44.19 M(-5.2%) |
| Sept 2022 | - | -$10.67 M(-10.6%) | -$46.61 M(+0.0%) |
| June 2022 | - | -$11.94 M(-3.6%) | -$46.61 M(+1.6%) |
| Mar 2022 | - | -$12.39 M(+6.8%) | -$45.89 M(+1.8%) |
| Dec 2021 | -$45.08 M(+18.5%) | -$11.61 M(+8.8%) | -$45.08 M(+3.8%) |
| Sept 2021 | - | -$10.67 M(-5.0%) | -$43.43 M(+4.2%) |
| June 2021 | - | -$11.22 M(-3.1%) | -$41.67 M(+6.0%) |
| Mar 2021 | - | -$11.58 M(+16.4%) | -$39.32 M(+3.3%) |
| Dec 2020 | -$38.05 M(-14.6%) | -$9.96 M(+11.8%) | -$38.05 M(-3.5%) |
| Sept 2020 | - | -$8.91 M(+0.4%) | -$39.44 M(-3.4%) |
| June 2020 | - | -$8.87 M(-14.0%) | -$40.81 M(-1.3%) |
| Mar 2020 | - | -$10.31 M(-9.1%) | -$41.37 M(-7.1%) |
| Dec 2019 | -$44.55 M(+299.2%) | -$11.34 M(+10.3%) | -$44.55 M(+7.5%) |
| Sept 2019 | - | -$10.28 M(+9.1%) | -$41.42 M(+133.2%) |
| June 2019 | - | -$9.43 M(-30.1%) | -$17.76 M(+16.1%) |
| Mar 2019 | - | -$13.49 M(+64.2%) | -$15.30 M(+37.1%) |
| Dec 2018 | -$11.16 M(-73.1%) | -$8.22 M(-161.4%) | -$11.16 M(+3.0%) |
| Sept 2018 | - | $13.38 M(-292.2%) | -$10.84 M(-65.1%) |
| June 2018 | - | -$6.96 M(-25.6%) | -$31.03 M(-23.8%) |
| Mar 2018 | - | -$9.36 M(+18.5%) | -$40.73 M(-2.0%) |
| Dec 2017 | -$41.54 M(+43.9%) | -$7.90 M(+15.8%) | -$41.54 M(-26.2%) |
| Sept 2017 | - | -$6.82 M(-59.1%) | -$56.27 M(-18.0%) |
| June 2017 | - | -$16.65 M(+63.7%) | -$68.65 M(-5356.2%) |
| Mar 2017 | - | -$10.17 M(-55.0%) | $1.31 M(-104.5%) |
| Dec 2016 | -$28.88 M(-77.2%) | -$22.63 M(+17.9%) | -$28.88 M(-36.2%) |
| Sept 2016 | - | -$19.19 M(-136.0%) | -$45.27 M(-362.4%) |
| June 2016 | - | $53.30 M(-232.1%) | $17.25 M(-123.2%) |
| Mar 2016 | - | -$40.35 M(+3.4%) | -$74.37 M(-41.3%) |
| Dec 2015 | -$126.67 M(+1570.3%) | -$39.02 M(-190.1%) | -$126.67 M(-0.1%) |
| Sept 2015 | - | $43.34 M(-213.1%) | -$126.77 M(+103.3%) |
| June 2015 | - | -$38.33 M(-58.6%) | -$62.35 M(+5.5%) |
| Mar 2015 | - | -$92.66 M(+136.8%) | -$59.11 M(+679.4%) |
| Dec 2014 | -$7.58 M(-94.1%) | -$39.13 M(-136.3%) | -$7.58 M(+232.6%) |
| Sept 2014 | - | $107.75 M(-407.1%) | -$2.28 M(-98.4%) |
| June 2014 | - | -$35.09 M(-14.7%) | -$143.97 M(+1.8%) |
| Mar 2014 | - | -$41.13 M(+21.6%) | -$141.48 M(+10.8%) |
| Dec 2013 | -$127.68 M(+145.3%) | -$33.82 M(-0.3%) | -$127.68 M(-9.3%) |
| Sept 2013 | - | -$33.94 M(+4.1%) | -$140.84 M(+60.1%) |
| June 2013 | - | -$32.59 M(+19.3%) | -$87.97 M(+26.9%) |
| Mar 2013 | - | -$27.33 M(-41.8%) | -$69.34 M(+33.2%) |
| Dec 2012 | -$52.06 M(+36.3%) | -$46.98 M(-348.1%) | -$52.06 M(+180.0%) |
| Sept 2012 | - | $18.94 M(-235.6%) | -$18.59 M(-62.1%) |
| June 2012 | - | -$13.97 M(+39.1%) | -$49.04 M(+5.6%) |
| Mar 2012 | - | -$10.04 M(-25.7%) | -$46.44 M(+21.0%) |
| Dec 2011 | -$38.20 M | -$13.52 M(+17.4%) | -$38.36 M(+0.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2011 | - | -$11.51 M(+1.3%) | -$38.36 M(-20.0%) |
| June 2011 | - | -$11.37 M(+477.8%) | -$47.98 M(+13.8%) |
| Mar 2011 | - | -$1.97 M(-85.4%) | -$42.14 M(-12.2%) |
| Dec 2010 | -$47.77 M(+57.6%) | -$13.52 M(-36.0%) | -$48.00 M(+16.9%) |
| Sept 2010 | - | -$21.13 M(+281.9%) | -$41.06 M(+42.4%) |
| June 2010 | - | -$5.53 M(-29.3%) | -$28.83 M(-21.1%) |
| Mar 2010 | - | -$7.83 M(+19.1%) | -$36.52 M(-20.3%) |
| Dec 2009 | -$30.31 M(-228.0%) | -$6.57 M(-26.1%) | -$45.84 M(-545.7%) |
| Sept 2009 | - | -$8.89 M(-32.8%) | $10.28 M(+66.9%) |
| June 2009 | - | -$13.23 M(-22.8%) | $6.16 M(-17.1%) |
| Mar 2009 | - | -$17.14 M(-134.6%) | $7.43 M(-68.6%) |
| Dec 2008 | $23.68 M(-201.7%) | $49.55 M(-480.8%) | $23.68 M(-167.3%) |
| Sept 2008 | - | -$13.01 M(+8.8%) | -$35.18 M(+36.8%) |
| June 2008 | - | -$11.96 M(+1226.4%) | -$25.73 M(+31.7%) |
| Mar 2008 | - | -$901.50 K(-90.3%) | -$19.54 M(-16.1%) |
| Dec 2007 | -$23.29 M(-13.0%) | -$9.31 M(+161.6%) | -$23.29 M(+31.6%) |
| Sept 2007 | - | -$3.56 M(-38.3%) | -$17.70 M(-6.2%) |
| June 2007 | - | -$5.77 M(+24.0%) | -$18.86 M(-7.9%) |
| Mar 2007 | - | -$4.65 M(+25.3%) | -$20.48 M(-23.5%) |
| Dec 2006 | -$26.76 M(-26.6%) | -$3.71 M(-21.4%) | -$26.76 M(-18.6%) |
| Sept 2006 | - | -$4.72 M(-36.1%) | -$32.87 M(-12.9%) |
| June 2006 | - | -$7.39 M(-32.4%) | -$37.73 M(+14.5%) |
| Mar 2006 | - | -$10.93 M(+11.3%) | -$32.95 M(+24.8%) |
| Dec 2005 | -$36.47 M(+8.3%) | -$9.83 M(+2.6%) | -$26.40 M(-49.1%) |
| Sept 2005 | - | -$9.58 M(+265.7%) | -$51.85 M(+23.8%) |
| June 2005 | - | -$2.62 M(-40.2%) | -$41.87 M(+8.2%) |
| Mar 2005 | - | -$4.38 M(-87.6%) | -$38.69 M(+14.9%) |
| Dec 2004 | -$33.69 M(-3095.7%) | -$35.28 M(-8891.4%) | -$33.69 M(-1340.6%) |
| Sept 2004 | - | $401.30 K(-28.5%) | $2.72 M(-1.5%) |
| June 2004 | - | $561.30 K(-11.0%) | $2.76 M(+34.5%) |
| Mar 2004 | - | $631.00 K(-43.8%) | $2.05 M(+77.8%) |
| Dec 2003 | $1.12 M(-101.7%) | $1.12 M(+152.7%) | $1.15 M(-102.0%) |
| Sept 2003 | - | $443.90 K(-402.8%) | -$58.66 M(-3.0%) |
| June 2003 | - | -$146.60 K(-44.9%) | -$60.50 M(-4.5%) |
| Mar 2003 | - | -$265.90 K(-99.5%) | -$63.34 M(-1.6%) |
| Dec 2002 | -$64.38 M(+339.6%) | -$58.69 M(+4108.1%) | -$64.38 M(+390.0%) |
| Sept 2002 | - | -$1.39 M(-53.3%) | -$13.14 M(-30.6%) |
| June 2002 | - | -$2.99 M(+128.1%) | -$18.94 M(+6.6%) |
| Mar 2002 | - | -$1.31 M(-82.4%) | -$17.77 M(-4.9%) |
| Dec 2001 | -$14.65 M(+250.2%) | -$7.45 M(+3.5%) | -$18.70 M(+44.1%) |
| Sept 2001 | - | -$7.20 M(+296.1%) | -$12.97 M(+76.3%) |
| June 2001 | - | -$1.82 M(-18.7%) | -$7.36 M(+23.1%) |
| Mar 2001 | - | -$2.23 M(+29.3%) | -$5.98 M(+43.0%) |
| Dec 2000 | -$4.18 M(+21.3%) | -$1.73 M(+9.2%) | -$4.18 M(+70.4%) |
| Sept 2000 | - | -$1.58 M(+263.7%) | -$2.45 M(+181.5%) |
| June 2000 | - | -$435.10 K(-0.4%) | -$871.80 K(+99.6%) |
| Mar 2000 | - | -$436.70 K | -$436.70 K |
| Dec 1999 | -$3.45 M | - | - |
FAQ
- What is Infinity Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals annual EBIT year-on-year change?
- What is Infinity Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals quarterly EBIT year-on-year change?
- What is Infinity Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Infinity Pharmaceuticals?
- What is Infinity Pharmaceuticals TTM EBIT year-on-year change?
What is Infinity Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of INFI is -$44.19 M
What is the all time high annual EBIT for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high annual earnings before interest & taxes is $25.65 M
What is Infinity Pharmaceuticals annual EBIT year-on-year change?
Over the past year, INFI annual earnings before interest & taxes has changed by +$893.00 K (+1.98%)
What is Infinity Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of INFI is -$9.91 M
What is the all time high quarterly EBIT for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high quarterly earnings before interest & taxes is $107.75 M
What is Infinity Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, INFI quarterly earnings before interest & taxes has changed by +$2.03 M (+17.00%)
What is Infinity Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of INFI is -$40.77 M
What is the all time high TTM EBIT for Infinity Pharmaceuticals?
Infinity Pharmaceuticals all-time high TTM earnings before interest & taxes is $23.68 M
What is Infinity Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, INFI TTM earnings before interest & taxes has changed by +$5.84 M (+12.53%)